Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3412745 | 0.97 | MEN1 (0.33) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL16877918 | 0.91 | ALDH1A1 (0.31) | CYP2C9 | |
| SCHEMBL16877360 | 0.87 | MEN1 (0.46) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Oxalic Acid SCHEMBL30362711 | 0.87 | CYP1A2 (0.31) | — | |
| SCHEMBL23309827 | 0.85 | — | — | |
| SCHEMBL19045057 | 0.85 | — | — | |
| SCHEMBL2538582 | 0.85 | — | — | |
| SCHEMBL19045056 | 0.85 | — | — | |
| SCHEMBL23508651 | 0.85 | MEN1 (0.32) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL503340 | 0.85 | ALDH1A1 (0.33) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070278-A | Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof | 标新生物医药科技(上海)有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4646263-A1 | SPRK1 INHIBITORS AND METHODS OF USE | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | claimed |
| EP-4590672-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | Merck Sharp & Dohme LLC (US) | 2025-07-30 | — | — | EP | claimed |
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119907797-A | Phthalazine derivatives as NOD-like receptor protein 3 inhibitors | 默沙东有限责任公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119654316-A | Thioglutarimide isoindolinone skeleton-based compound and application thereof | 标新生物医药科技(上海)有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119604494-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119451952-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione derivative and application thereof | 标新生物医药科技(上海)有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2024213032-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 纽欧申医药(上海)有限公司 | 2024-10-17 | — | — | WO | claimed |
| EP-2611777-B1 | N-(4-{[PYRIDIN-3-YL-METHYL)CARBAMOYL]AMINO}BENZENE-SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM LLC (US) | 2016-05-11 | — | — | EP | claimed |
| EP-2528910-B1 | 5-Alkynyl pyrimidines ahd their use as kinase inhibitors. | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8618111-B2 | 5-alkynyl-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | claimed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | claimed |
| EP-2528910-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | claimed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| US-20120028958-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | claimed |
| WO-2011092197-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028958-A1 | 5-ALKYNYL-PYRIMIDINES | MKI67, CCNA1, CCNT1 | MEN1 2235/4885KMT2A 2597/4885KDM4E 1424/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | MEN1 582/4885KMT2A 1615/4885KDM4E 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.